Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Neurology Diabetes / Metabolic Women's Health Rheumatology Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Trial Radar • ClinicalTrials.gov • Registry-linked

Trial Radar

2236 clinical trials with phase, status, specialty and registry links, summarised for rapid clinical review.

2236 recruiting AI clinical summaries
Explore Trial Collections Follow research updates
All Phases Phase I Phase II Phase III Phase IV
Therapeutic Area: All Cardiology / Cardiovascular Dermatology Diabetes / Metabolic Gastroenterology Haematology Infectious Disease Men's Health Mental Health / Psychiatry Nephrology Neurology Oncology Rare Diseases
🔬
Trial Radar

Clinical Trial Intelligence

● Recruiting Phase I Oncology
A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies
What is being tested: ZI-MA4-1, a novel therapeutic agent, is undergoing evaluation for safety, tolerability, and clinical efficacy in patients with advanced solid malignancies…
29 May 2026 NCT07613723
● Recruiting Phase I Neurology
A Study to Assess the Effects of ACI-24.060 in Alzheimer’s Disease and in Down Syndrome (ABATE Study)
What is being tested: ACI-24.060, an investigational therapeutic agent, is being evaluated for its safety, tolerability, immunogenicity, and pharmacodynamic effects in two distinct populations:…
29 May 2026 NCT05462106
● Recruiting Respiratory / COPD / Asthma
Better Tests- Improving Diagnostic Accuracy and Prognostication in Interstitial Lung Diseases
What is being tested: Non-invasive diagnostic assessments designed to improve diagnostic accuracy and prognostication in interstitial lung diseases (ILD), addressing current weaknesses in available…
29 May 2026 NCT07615504
● Recruiting Phase III Respiratory / COPD / Asthma
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
What is being tested: Daraxonrasib (RMC-6236), a novel RAS(ON) inhibitor, is being evaluated against docetaxel chemotherapy for safety and efficacy in patients with RAS-mutated…
29 May 2026 NCT06881784
● Recruiting Phase III Cardiology / Cardiovascular
Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bempedoic Acid to Treat Dyslipidemia in Adults With Primary Non-familial Hypercholesterolemia or Mixed Dyslipidemia at High to Very High Cardiovascular Risk, During a Treatment Period of Approximately 84 Days
What is being tested: Obicetrapib (OBI), a novel CETP inhibitor, is being directly compared to bempedoic acid (BPA) for reducing LDL-cholesterol in adults with…
29 May 2026 NCT07614958
● Recruiting Phase III Cardiology / Cardiovascular
A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
What is being tested: L606 is being evaluated in a Phase 3 trial to assess its safety and efficacy in treating pulmonary hypertension secondary…
29 May 2026 NCT07285655
● Recruiting Phase II Oncology
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
What is being tested: This trial investigates ribociclib (CDK4/6 inhibitor) combined with either everolimus or temozolomide in pediatric and young adult patients with newly…
29 May 2026 NCT05843253
● Recruiting Oncology
Bearing nsPVA Embolization for Uterine Artery Embolization (BETTER-UAE)
What is being tested: Safety and performance of Bearing nsPVA (non-spherical polyvinyl alcohol) embolization particles as an embolic agent for uterine artery embolization in…
29 May 2026 NCT06153667
active not recruiting Phase III
Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP
A new drug (ALXN1850) was tested against placebo in children with bone disease to see if it improves bone health.
28 May 2026 NCT06079359
active not recruiting Phase IV Gastroenterology
Stopping Aminosalicylate Therapy in Inactive Crohn’s Disease
Stopping 5-ASA medication in inactive Crohn's disease works as well as continuing it.
28 May 2026 NCT03261206
● Recruiting Phase III
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
A new drug (empasiprubart) is being tested to see if it safely improves symptoms in adults with chronic nerve inflammation (CIDP).
28 May 2026 NCT07091630
active not recruiting Phase I / Phase II Oncology
A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)
MTAPESTRY 101 Summary Trial testing anvumetostat drug alone and with chemotherapy in patients with MTAP-null cancers to find safe doses and effectiveness.
28 May 2026 NCT05094336
● Recruiting Phase III Diabetes / Metabolic
A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs
A new drug (Debio 4126) tested against placebo to control growth hormone levels in acromegaly patients previously treated with somatostatin analogs.
28 May 2026 NCT06930625
● Recruiting Phase III Oncology
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
What is being tested: AZD2265, a novel therapeutic agent, is being evaluated against standard-of-care treatments in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC),…
28 May 2026 NCT07611110
● Recruiting Phase III Oncology
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
What is being tested: Camizestrant (AZD9833), a selective oestrogen receptor degrader (SERD), is being compared to standard adjuvant endocrine therapy (aromatase inhibitors or tamoxifen)…
28 May 2026 NCT05952557
● Recruiting Phase II Oncology
Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer
Treatment being tested: Camizestrant (an ER degrader) combined with atirmociclib (a CDK4/6 inhibitor) in women with ER-positive, HER2-negative advanced breast cancer who have previously…
28 May 2026 NCT07427394
● Recruiting Cardiology / Cardiovascular
A Study to Check Liver Health in Boys With XLMTM, a Serious Genetic Muscle Condition
What is being tested: This study evaluates liver health and function in boys with XLMTM (X-linked myotubular myopathy), a severe genetic muscle disorder caused…
28 May 2026 NCT06581146
● Recruiting Cardiology / Cardiovascular
The Effect of Time-Restricted Eating in Cardiometabolic Health
What is being tested: Time-restricted eating (TRE)—limiting daily food intake to a 6-12 hour window—is being investigated for its effects on cardiometabolic health markers,…
28 May 2026 NCT05866406
● Recruiting Phase I Cardiology / Cardiovascular
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
What is being tested: A phase 1b/2 dose-escalation and expansion study evaluating mezigdomide (cereblon E3 ligase modulator) combined with elranatamab (GPRC5D-targeted bispecific antibody) to…
28 May 2026 NCT06988488
● Recruiting Cardiology / Cardiovascular
Low-dose Interleukin-2 After Myocardial Infarction to Investigate Effects on Tissue-resident Regulatory T Cells
What is being tested: Low-dose interleukin-2 (ld-IL-2) administration in post-myocardial infarction patients to determine its effects on tissue-resident regulatory T cells (Tregs), assessed through…
28 May 2026 NCT07610538
● Recruiting Phase III Oncology
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
What is being tested: Long-term safety profile of luspatercept (ACE-536) in patients transitioning from completed or concluded parent clinical trials, using an open-label rollover…
28 May 2026 NCT04064060
● Recruiting Phase III Oncology
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
What is being tested: Zolbetuximab (a monoclonal antibody targeting claudin-18.2) combined with pembrolizumab (PD-1 inhibitor) and chemotherapy as a treatment for advanced gastric and…
28 May 2026 NCT06901531
active not recruiting Phase III Oncology
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
DESTINY-Gastric04 Summary Trastuzumab deruxtecan improves survival compared with ramucirumab plus paclitaxel in HER2-positive gastric cancer after trastuzumab treatment.
27 May 2026 NCT04704934
● Recruiting Cardiology / Cardiovascular
FORWARD CAD IDE Study
Shockwave lithotripsy catheter safely and effectively treats hard calcium buildup in coronary arteries before stent placement.
27 May 2026 NCT06662500
active not recruiting Phase III Rheumatology
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis
Bimekizumab compared to risankizumab for treating active psoriatic arthritis over 16 weeks.
27 May 2026 NCT06624228
● Recruiting Respiratory / COPD / Asthma
Electrical Impedance Tomography & Selective Stimulation of Vagus Nerve
Researchers will map which parts of the vagus nerve control specific organs using selective stimulation and imaging during vagal nerve stimulator surgery.
27 May 2026 NCT05664854
● Recruiting Phase III
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington’s Disease
A trial testing whether votoplam slows Huntington's disease progression in early symptomatic patients compared with placebo.
27 May 2026 NCT07326709
● Recruiting Phase III
A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
A trial testing whether nipocalimab injection safely prevents severe low platelet counts in babies of at-risk pregnant women.
27 May 2026 NCT06533098
active not recruiting Phase III
Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta
Romosozumab versus bisphosphonates for reducing fractures and improving bone density in children with osteogenesis imperfecta over 12 months.
27 May 2026 NCT05972551
active not recruiting
DiamondTemp Global Registry
A worldwide study tracking how the DiamondTemp device performs in real-world patient care across multiple hospitals.
27 May 2026 NCT04735016
● Recruiting Phase I Oncology
A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.
What is being tested: [177Lu]Lu-NeoB, a novel radioligand therapeutic targeting GRPR-positive tumours, combined with capecitabine chemotherapy in a dose-escalation study to establish safe and…
27 May 2026 NCT06247995
● Recruiting Phase I Oncology
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
What is being tested: Zanzalintinib (a novel therapeutic agent) is being evaluated as monotherapy and in combination with immune checkpoint inhibitors (nivolumab ± ipilimumab)…
27 May 2026 NCT05176483
● Recruiting Phase III Oncology
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn’s Disease
What is being tested: The efficacy of dual targeted therapy combining vedolizumab (α4β7 integrin inhibitor) and upadacitinib (JAK inhibitor) versus vedolizumab monotherapy in reducing…
27 May 2026 NCT06227910
● Recruiting Phase I Oncology
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
What is being tested: TUB-040, a novel NaPi2b antibody-drug conjugate (ADC), is being investigated in a first-in-human trial to establish safety, tolerability, pharmacokinetics, and…
27 May 2026 NCT06303505
● Recruiting Phase III Oncology
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Treatment being tested: A fixed-duration combination of sonrotoclax (a novel BCL2 inhibitor) plus zanubrutinib (a Bruton tyrosine kinase inhibitor) compared to the established venetoclax…
27 May 2026 NCT07277231
● Recruiting
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
Study tracking disease progression and treatment outcomes in patients with ATTR amyloidosis, including the new drug eplontersen.
26 May 2026 NCT06465810
active not recruiting Phase III Oncology
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
Testing whether adding pembrolizumab and olaparib to chemotherapy and radiation improves survival in early-stage small cell lung cancer.
26 May 2026 NCT04624204
● Recruiting
EXtubation Related Complications – the EXTUBE Study (EXTUBE)
EXTUBE tracked complications after removing breathing tubes in anesthetised and critically ill patients across multiple hospitals worldwide.
26 May 2026 NCT06442930
● Recruiting Phase II Mental Health / Psychiatry
An Open-Label Study to Evaluate the Safety, Tolerability and Pharmacodynamics of BPL-003 in Patients With Treatment Resistant Depression
BPL-003 Trial Summary Intranasal BPL-003 with psychological support tested for safety and effectiveness in treatment-resistant depression, used alone or with SSRIs.
26 May 2026 NCT05660642
active not recruiting Oncology
Improving Uptake of Bowel Cancer Screening Among South Asian Adults in Bradford
Study tests whether culturally tailored screening materials and a biodegradable collection tool increase bowel cancer screening uptake among South Asian adults in Bradford.
26 May 2026 NCT07376694
● Recruiting Phase I / Phase II
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
ETX101 gene therapy trial testing safety and effectiveness in infants and children with Dravet syndrome.
26 May 2026 NCT05419492
active not recruiting Phase III Oncology
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
GLORIOSA Trial Summary Adding mirvetuximab soravtansine to bevacizumab improves outcomes in platinum-sensitive ovarian cancer with high folate receptor expression.
26 May 2026 NCT05445778
● Recruiting Phase I Cardiology / Cardiovascular
A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias
Drug being tested: CTX310 is undergoing Phase 1 evaluation in a single-arm, open-label design with ascending doses to establish safety and tolerability in adults…
26 May 2026 NCT07491172
● Recruiting Phase III Oncology
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Treatment being tested: Trastuzumab deruxtecan (T-DXd), a HER2-targeted antibody-drug conjugate, combined with bevacizumab versus bevacizumab alone as first-line maintenance therapy in patients with HER2-expressing…
26 May 2026 NCT06819007
● Recruiting Phase II Oncology
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
What is being tested: Volrustomig, a novel anti-cancer agent, is being evaluated both as a standalone treatment and combined with existing anti-cancer drugs in…
26 May 2026 NCT06535607
● Recruiting Phase III Oncology
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
What is being tested: Dostarlimab (a PD-1 checkpoint inhibitor) versus placebo as maintenance therapy following chemoradiation in patients with locally advanced, unresectable head and…
26 May 2026 NCT06256588
● Recruiting Women's Health
Whole-Body Cryotherapy as a Non-Pharmacological Treatment to Reduce Chronic Pelvic Pain and Improve Quality of Life in People With Endometriosis
Trial tests whether brief extreme cold exposure reduces endometriosis pain and improves quality of life in thirty participants.
22 May 2026 NCT07603960
active not recruiting Phase III
A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)
A gene therapy trial testing whether a single infusion can slow muscle weakness in boys with Duchenne muscular dystrophy.
22 May 2026 NCT05881408
● Recruiting Phase II
A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)
Trial testing new drug LY4005130 versus placebo for severe hair loss, measuring effectiveness, safety, and how body processes drug.
22 May 2026 NCT07533006
● Recruiting Phase II
A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves’ Disease
A trial testing whether rilzabrutinib improves Graves' disease symptoms and safety over 16 weeks in two dose groups.
22 May 2026 NCT06984627